Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
After finishing at $122.88 in the prior trading day, GeneDx Holdings Corp (NASDAQ: WGS) closed at $126.36, up 2.83%. In other words, the price has increased by $2.83 from its previous closing price. On the day, 0.83 million shares were traded. WGS stock price reached its highest trading level at $127.3 during the session, while it also had its lowest trading level at $121.0.
Ratios:
Our goal is to gain a better understanding of WGS by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 26.98 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 4373.31. For the most recent quarter (mrq), Quick Ratio is recorded 2.70 and its Current Ratio is at 2.87. In the meantime, Its Debt-to-Equity ratio is 0.42 whereas as Long-Term Debt/Eq ratio is at 0.40.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Piper Sandler on July 09, 2025, initiated with a Overweight rating and assigned the stock a target price of $110.
On May 15, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $88.
Jefferies Upgraded its Hold to Buy on May 09, 2025, while the target price for the stock was maintained at $80.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 29 ’25 when Feeley Kevin sold 388 shares for $105.31 per share. The transaction valued at 40,860 led to the insider holds 3,757 shares of the business.
Stueland Katherine sold 2,154 shares of WGS for $226,838 on Jul 29 ’25. The Chief Executive Officer now owns 3,440 shares after completing the transaction at $105.31 per share. On Jul 09 ’25, another insider, Feeley Kevin, who serves as the CHIEF FINANCIAL OFFICER of the company, sold 5,278 shares for $93.00 each. As a result, the insider received 490,854 and left with 3,392 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, WGS now has a Market Capitalization of 3629842688 and an Enterprise Value of 3609675776. As of this moment, GeneDx’s Price-to-Earnings (P/E) ratio for their current fiscal year is 6757.22, and their Forward P/E ratio for the next fiscal year is 54.51. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 50.34. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.02 while its Price-to-Book (P/B) ratio in mrq is 13.09. Its current Enterprise Value per Revenue stands at 9.963 whereas that against EBITDA is 121.969.
Stock Price History:
The Beta on a monthly basis for WGS is 2.09, which has changed by 2.5564313 over the last 52 weeks, in comparison to a change of 0.15005577 over the same period for the S&P500. Over the past 52 weeks, WGS has reached a high of $123.81, while it has fallen to a 52-week low of $28.86. The 50-Day Moving Average of the stock is 43.44%, while the 200-Day Moving Average is calculated to be 52.07%.
Shares Statistics:
The stock has traded on average 910.92K shares per day over the past 3-months and 731010 shares per day over the last 10 days, according to various share statistics. A total of 28.71M shares are outstanding, with a floating share count of 25.05M. Insiders hold about 12.79% of the company’s shares, while institutions hold 110.13% stake in the company. Shares short for WGS as of 1753920000 were 3639624 with a Short Ratio of 4.00, compared to 1751241600 on 3673798. Therefore, it implies a Short% of Shares Outstanding of 3639624 and a Short% of Float of 25.4.
Earnings Estimates
The market rating for GeneDx Holdings Corp (WGS) is a result of the insights provided by 5.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is $0.59, with high estimates of $0.66 and low estimates of $0.51.
Analysts are recommending an EPS of between $2.0 and $1.56 for the fiscal current year, implying an average EPS of $1.74. EPS for the following year is $2.37, with 6.0 analysts recommending between $2.6 and $2.17.
Revenue Estimates
7 analysts predict $104.11M in revenue for the current quarter. It ranges from a high estimate of $105.4M to a low estimate of $102.8M. As of the current estimate, GeneDx Holdings Corp’s year-ago sales were $76.87MFor the next quarter, 7 analysts are estimating revenue of $116.87M. There is a high estimate of $117.4M for the next quarter, whereas the lowest estimate is $115.4M.
A total of 7 analysts have provided revenue estimates for WGS’s current fiscal year. The highest revenue estimate was $412.4M, while the lowest revenue estimate was $408.05M, resulting in an average revenue estimate of $410.79M. In the same quarter a year ago, actual revenue was $305.45MBased on 7 analysts’ estimates, the company’s revenue will be $486.62M in the next fiscal year. The high estimate is $510.1M and the low estimate is $475.03M.
